NewsDialy

Radiopharma giants merge in $1.65 billion deal after FDA rejection

9/21/2026

Two leading radiopharmaceutical companies are merging in a transaction valued at at least $1.65 billion. This move follows a surprise FDA rejection for one of the firms.

In plain terms, radiopharmaceuticals are medicines that deliver radioactive isotopes directly to cancer cells to treat disease.

The deal combines ITM Isotope Technologies Munich SE and Telix Pharmaceuticals, creating a larger competitor in a field currently dominated by Novartis.

Here is what that means for the industry structure and the specific terms of this agreement.